Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...

Older AA/PNH patients who have myeloid driver mutations at baseline and a poor response to nontransplant treatment have a higher risk of progression to sMN. Baseline-prevalent mutations (PIGA/human ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by a mutation in the PIGA gene. This mutation causes defective hematopoietic stem cells, which develop into defective red blood ...

Iptacopan, the first oral monotherapy for patients with paroxysmal nocturnal hemoglobinuria (PNH), is now an FDA-approved option for improving hemoglobin levels. Iptacopan (Fabhalta) was granted ...

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH. Carlos M. De Castro, MD: If you look at complements, they’re activated in 3 ways. There’s the classical pathway, an ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...